Shares of other companies:
April 19, 2024 Bitcoin Halving: Catalyst for New Price Heights?
April 18, 2024 EU Moves Toward Single Capital Market Union
April 17, 2024 Bitcoin Halving 2024: Market Impact Predictions
Wall Street Lunch: Big Tech Bearishness?
April 22, 2024
Apple Should Climb The Wall Of Worry
April 20, 2024
Microsoft Q3 Preview: Focusing On Copilot
April 19, 2024
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
April 12, 2024 Improve Your Financial Status: A How-To Guide
Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade
Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
EBS Stock News and Mentions of Emergent BioSolutions Inc. Stocktwits
Updated: April 23, 2024 (10:18)
Sector: Healthcare
Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights. Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.
We meticulously analyze the sentiment trend in each article for the last 60 days where Emergent BioSolutions Company is mentioned. We assess its relevance and importance to carry out an overall sentiment valuation of Emergent BioSolutions Inc. (EBS).
You can view the trend designation for each individual article below. We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the Emergent BioSolutions stocks.
Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles
News and Mentions of Emergent BioSolutions Inc. (EBS)
April 22, 2024 (12:05) / "Benzinga" (by Globe Newswire)
Emergent BioSolutions to Release First Quarter 2024 Financial Results & Conduct Conference Call on May 1, 2024 - Emergent BioSolutions ( NYSE:EBS )
GAITHERSBURG, Md., April 22, 2024 ( GLOBE NEWSWIRE ) -- Emergent BioSolutions Inc. EBS will host a conference call on Wednesday, May 1, 2024, at 5:00 pm eastern time to discuss the financial results for the first quarter 2024, key business updates, revenue guidance for the second quarter of 2024, ...
In Article Trend: Somewhat-Bullish
April 22, 2024 (12:05) / "GlobeNewswire" (by Inc.)
Emergent BioSolutions to Release First Quarter 2024 Financial Results & Conduct Conference Call on May 1, 2024
GAITHERSBURG, Md., April 22, 2024 ( GLOBE NEWSWIRE ) -- Emergent BioSolutions Inc. ( NYSE: EBS ) will host a conference call on Wednesday, May 1, 2024, at 5:00 pm eastern time to discuss the financial results for the first quarter 2024, key business updates, revenue guidance for the second ...
In Article Trend: Somewhat-Bullish
April 8, 2024 (11:30) / "GlobeNewswire" (by XORTX Therapeutics Inc.)
XORTX Welcomes New Member to the Board of Directors
CALGARY, Alberta, April 08, 2024 ( GLOBE NEWSWIRE ) -- XORTX Therapeutics Inc. ( "XORTX" or the "Company" ) ( NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ ) , a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, ...
In Article Trend: Somewhat-Bullish
April 8, 2024 (11:30) / "Benzinga" (by Globe Newswire)
XORTX Welcomes New Member to the Board of Directors - Gamida Cell ( NASDAQ:GMDA )
CALGARY, Alberta, April 08, 2024 ( GLOBE NEWSWIRE ) -- XORTX Therapeutics Inc. ( "XORTX" or the "Company" ) XRTXXRTXANUA ) ) , a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, welcomes Abigail Jenkins, a biotech industry ...
In Article Trend: Somewhat-Bullish
March 28, 2024 (12:15) / "Benzinga" (by Globe Newswire)
Emergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN® Nasal Spray to Help Save Lives from the Ongoing Opioid Crisis - Emergent BioSolutions ( NYSE:EBS )
As the first-ever U.S. Food and Drug Administration ( FDA ) approved over-the-counter ( OTC ) naloxone in 2023, Emergent is working to expand access with NARCAN® Nasal Spray and build on its longstanding efforts with public interest entities across the country
In Article Trend: Neutral
March 28, 2024 (12:15) / "GlobeNewswire" (by Emergent Biosolutions)
Emergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN® Nasal Spray to Help Save Lives from the Ongoing Opioid Crisis
GAITHERSBURG, Md., March 28, 2024 ( GLOBE NEWSWIRE ) -- Emergent BioSolutions Inc. ( NYSE: EBS ) remains committed to fighting the ongoing opioid crisis by broadening access to, and awareness of, NARCAN® Nasal Spray to help save lives in opioid overdose emergencies. In 2022, the U.S.
In Article Trend: Neutral
March 26, 2024 (06:00) / "Benzinga" (by Globe Newswire)
Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate
Saint-Herblain ( France ) , March 26, 2024 - Valneva SE VALNVLA, a specialty vaccine company, today announced the initiation of a Phase 1 clinical trial to investigate the the safety and immunogenicity of VLA1601, its second-generation adjuvanted inactivated vaccine candidate against the Zika ...
In Article Trend: Neutral
March 26, 2024 (06:00) / "GlobeNewswire" (by VALNEVA)
Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate
Saint-Herblain ( France ) , March 26, 2024 - Valneva SE ( Nasdaq: VALN. Euronext Paris: VLA ) , a specialty vaccine company, today announced the initiation of a Phase 1 clinical trial to investigate the ...
In Article Trend: Neutral
March 25, 2024 (12:05) / "GlobeNewswire" (by Emergent Biosolutions)
Emergent BioSolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility
GAITHERSBURG, Md., March 25, 2024 ( GLOBE NEWSWIRE ) -- Emergent BioSolutions Inc. ( NYSE: EBS ) announced that the U.S. Food and Drug Administration ( FDA ) has listed "No Action Indicated" or NAI status classification for the company's Baltimore Bayview manufacturing facility.
In Article Trend: Somewhat-Bullish
March 25, 2024 (12:05) / "Benzinga" (by Globe Newswire)
Emergent BioSolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility - Emergent BioSolutions ( NYSE:EBS )
GAITHERSBURG, Md., March 25, 2024 ( GLOBE NEWSWIRE ) -- Emergent BioSolutions Inc. EBS announced that the U.S. Food and Drug Administration ( FDA ) has listed "No Action Indicated" or NAI status classification for the company's Baltimore Bayview manufacturing facility.
In Article Trend: Somewhat-Bullish
March 20, 2024 (06:00) / "Business Insider" (by markets.businessinsider.com)
Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook
Product sales surpassed pre-pandemic ( 2019 ) sales by 12% and 2022 sales by 26% Excluding COVID-19 vaccine sales, product sales grew by 63% compared to 2022 Cash position of €126.1 million at year-end 2023 enhanced by €95 million from sale of Priority Review Voucher ( PRV ) 1
In Article Trend: Somewhat-Bullish
March 20, 2024 (06:00) / "GlobeNewswire" (by VALNEVA)
Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook
Total revenues of €153.7 million, including product sales of €144.6 million ...
In Article Trend: Somewhat-Bullish
March 7, 2024 (17:34) / "Zacks Commentary" (by Zacks Equity Research)
Emergent ( EBS ) Down 16% on Q4 Earnings Miss, Tops on Sales
Emergent (EBS) reports mixed earnings for fourth-quarter 2023. The company signs a forbearance agreement with its lenders, effective till April 2023-end.
In Article Trend: Neutral
March 7, 2024 (13:05) / "Benzinga" (by Avi Kapoor)
Why Rush Street Interactive Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket - ADT ( NYSE:ADT ) , AudioEye ( NASDAQ:AEYE )
Shares of Rush Street Interactive, Inc. RSI rose sharply in today's pre-market trading as the company reported better-than-expected fourth-quarter financial results and issued strong revenue guidance for 2024.
In Article Trend: Somewhat-Bullish
March 7, 2024 (04:30) / "Motley Fool" (by Motley Fool Transcribing)
Emergent BioSolutions ( EBS ) Q4 2023 Earnings Call Transcript
EBS earnings call for the period ending December 31, 2023.
In Article Trend: Somewhat-Bullish
March 6, 2024 (22:55) / "Zacks Commentary" (by Zacks Equity Research)
Emergent Biosolutions ( EBS ) Reports Q4 Loss, Tops Revenue Estimates
Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -133.33% and 11.70%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
In Article Trend: Neutral
March 6, 2024 (22:02) / "Benzinga" (by Erica Kollmann)
Emergent BioSolutions Reports Q4 Results, Amends Credit Agreement - Emergent BioSolutions ( NYSE:EBS )
Emergent Biosolutions Inc EBS shares are trading higher after the company amended its existing credit agreement and reported its fourth-quarter financial results. Here's a look at the details.
In Article Trend: Somewhat-Bullish
March 6, 2024 (21:31) / "GlobeNewswire" (by Emergent Biosolutions)
Emergent BioSolutions Reports Fourth Quarter 2023 Financial Results
GAITHERSBURG, Md., March 06, 2024 ( GLOBE NEWSWIRE ) -- Emergent BioSolutions Inc. ( NYSE: EBS ) today reported financial results for the quarter and year ended December 31, 2023.
In Article Trend: Neutral
February 29, 2024 (12:00) / "Benzinga" (by Globe Newswire)
Emergent BioSolutions to Release Fourth Quarter & Full Year 2023 Financial Results, and Conduct Conference Call on March 6, 2024 - Emergent BioSolutions ( NYSE:EBS )
GAITHERSBURG, Md., Feb. 29, 2024 ( GLOBE NEWSWIRE ) -- Emergent BioSolutions Inc. EBS will host a conference call on Wednesday, March 6, 2024, at 5:00 pm eastern time to discuss the financial results for the fourth quarter and full year 2023. Emergent's newly appointed president and CEO, Joseph C.
In Article Trend: Neutral
February 29, 2024 (12:00) / "Benzinga" (by Globe Newswire)
Chimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational Update - Chimerix ( NASDAQ:CMRX )
- ONC201 ACTION Study Progressing; Reiterate Interim OS Data Expected in 2025, Final OS Data Expected in 2026 - - Phase 2 ONC201 Data Published in Peer-Reviewed Journal of Clinical Oncology - - $204 Million in Cash and Equivalents at December 31, 2023 - - Conference Call at 8:30 a.m. ET Today -
In Article Trend: Somewhat-Bullish
February 29, 2024 (12:00) / "GlobeNewswire" (by Emergent Biosolutions)
Emergent BioSolutions to Release Fourth Quarter & Full Year 2023 Financial Results, and Conduct Conference Call on March 6, 2024
GAITHERSBURG, Md., Feb. 29, 2024 ( GLOBE NEWSWIRE ) -- Emergent BioSolutions Inc. ( NYSE: EBS ) will host a conference call on Wednesday, March 6, 2024, at 5:00 pm eastern time to discuss the financial results for the fourth quarter and full year 2023. Emergent's newly appointed president and ...
In Article Trend: Somewhat-Bullish
Related stocks from Healthcare sector
This website uses cookies to ensure you get the best experience on our website